摘要
目的:探讨贝伐单抗联合白蛋白结合型紫杉醇治疗复发性卵巢癌临床疗效和安全性。方法:回顾性分析我院32例复发性卵巢癌经贝伐单抗联合白蛋白结合型紫杉醇治疗的临床资料,总结近期疗效和观察不良反应。结果:肿瘤控制总有效率46.9%,获益率75.0%;降低血清肿瘤标记物表达水平有效率53.1%;临床症状缓解率50.0%;不良反应按系统大致归类,以皮疹发生率最高、达84.2%,其次是消化道反应68.8%、继发高血压65.6%,蛋白尿和肝功能损害相对低,仅21.9%、18.8%,无出血和胃肠穿孔及血栓性事件。结论:贝伐单抗联合白蛋白结合型紫杉醇治疗复发性卵巢癌在控制肿瘤发展、降低血清肿瘤标记物表达水平、缓解临床症状等方面效果良好,不良反应发生率偏高但可耐受,对症处理可减轻,无严重不良事件,安全可行。
Objective: To investigate the clinical efficacy and safety of bevacizumab combined with albumin- bound paclitaxel in the treatment of recurrent ovarian cancer. Method: The clinical data of 32 cases of recurrent ovarian cancer treated with bevacizumab combined with albumin-binding paclitaxel in our hospital were retrospectively analyzed. We summarize the short-term curative effect and ob-serve the adverse reactions. Result: The total effective rate of tumor control was 46.9% and the benefit rate was 75.0%. The effective rate of reducing serum tumor marker expression level was 53.1%. The remission rate of clinical symptoms was 50.0%. The adverse reactions were generally classified according to the system. The incidence of rash was the highest (84.2%), followed by diges-tive tract reaction (68.8%), secondary hypertension (65.6%), proteinuria and liver function im-pairment were relatively low (21.9% and 18.8%), and there was no bleeding or thrombosis caused by gastrointestinal perforation. Conclusion: In the treatment of recurrent ovarian cancer, bevaci-zumab combined with albumin-binding paclitaxel has a good effect in controlling tumor develop-ment, reducing the expression level of serum tumor markers, and alleviating clinical symptoms. The incidence of adverse reactions is high and tolerable, and symptomatic treatment can be allevi-ated. There are no serious adverse events, and it is safe and feasible.
出处
《临床医学进展》
2022年第5期4929-4933,共5页
Advances in Clinical Medicine
